Home Cart Sign in  
Chemical Structure| 1073154-85-4 Chemical Structure| 1073154-85-4

Structure of Defactinib
CAS No.: 1073154-85-4

Chemical Structure| 1073154-85-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Defactinib (VS-6063; PF-04554878) represents a novel FAK inhibitor, exhibiting potential antiangiogenic and antineoplastic properties.

Synonyms: VS-6063; PF-04554878

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Defactinib

CAS No. :1073154-85-4
Formula : C20H21F3N8O3S
M.W : 510.49
SMILES Code : O=C(NC)C1=CC=C(NC2=NC=C(C(F)(F)F)C(NCC3=NC=CN=C3N(C)S(=O)(C)=O)=N2)C=C1
Synonyms :
VS-6063; PF-04554878
MDL No. :MFCD25977806
InChI Key :FWLMVFUGMHIOAA-UHFFFAOYSA-N
Pubchem ID :25117126

Safety of Defactinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Defactinib

RTK
cytoskeleton

Isoform Comparison

Biological Activity

Target
  • FAK

In Vitro:

Cell Line
Concentration Treated Time Description References
PC-9/PEM 3 μM 96 h Defactinib inhibited PTK2 phosphorylation and restored EGFR-TKI sensitivity PMC6889213
PC-9/PEM clone1 1 μM 96 h Defactinib combined with EGFR-TKI significantly induced apoptosis PMC6889213
Cdh1−/−RHOAY42C/+ organoids 2.5 μM 20 days To evaluate the inhibitory effect of Defactinib on Cdh1−/−RHOAY42C/+ organoids, it was found that CDK6 promoted resistance to Defactinib. PMC9812865
SNU668 cells 2.5 μM To validate whether CDK6 overexpression promotes resistance to Defactinib, results showed that CDK6 indeed promoted resistance to Defactinib. PMC9812865
Suit-2 2.0–5.0μM 72 h Defactinib reduced PDAC cell proliferation, validating the anti-tumor effect of FAK inhibition. PMC7941981
PDAC-1 1μM 24 h Defactinib significantly inhibited the migration ability of PDAC cells. PMC7941981
MCF10A cells 5 μM 24 h Assessed the effect of Defactinib on MCF10A cells, no cytotoxicity observed. PMC7316573
MDA-MB-231 10 µM 18 h Defactinib inhibited NGF-induced migration of MDA-MB-231 cells. PMC8275826
MDA-MB-453 10 µM 18 h Defactinib inhibited NGF-induced migration of MDA-MB-453 cells. PMC8275826
FM-93/2 5 µM 96 h Evaluate the effect of Defactinib on FM-93/2 cells, results showed AMBRA1LOW cells are more sensitive to FAKi PMC11194594
M24 5 µM 96 h Evaluate the effect of Defactinib on M24 cells, results showed AMBRA1LOW cells are more sensitive to FAKi PMC11194594

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/cA nu/nu mice Subcutaneous xenograft model Oral 25 mg/kg/d Twice daily for 5 days/week Combination of defactinib and osimertinib significantly inhibited tumor growth PMC6889213
NSG mice NUGC4 and SNU668 xenograft models Oral 50 mg/kg Twice daily for 3 weeks To evaluate the effect of Defactinib combined with CDK4/6 inhibitors, results showed that the combination therapy significantly inhibited tumor growth. PMC9812865
Mice FC1199 pancreatic cancer model Oral 15 mg/kg Twice daily for 12 days To test the inhibitory effect of Defactinib combined with Erdafitinib on the FC1199 pancreatic cancer model, the results showed that the combination significantly inhibited tumor growth. PMC10411016
Nude mice Orthotopic xenograft HCC model Oral 25 mg/kg Twice daily for eight weeks The combination of Defactinib and Linsitinib significantly suppressed BACH1-mediated HCC tumor growth and lung metastasis, and prolonged the survival of nude mice PMC8771560
Nude mice Orthotopic pancreatic cancer model Oral 25 mg/kg Twice daily for 2 cycles, each cycle lasting 5 days The combination of defactinib with nab-paclitaxel significantly inhibited tumor growth, while defactinib alone showed limited efficacy. PMC7941981
C57 BL/6 mice MC38 subcutaneous tumor model intraperitoneal injection 10 mg/kg daily for one week Inhibition of PYK2 or integrin β1 by Defactinib reduced SPON2-induced tumor growth and M2-TAMs infiltration. PMC8477524
Mice C57Bl/6 N mice Oral 50 mg/kg 21 days Evaluate the effect of Defactinib on mouse models, results showed FAKi alone or in combination with BRAFi can overcome BRAFi resistance PMC11194594

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01943292 Non Hematologic Cancers PHASE1 COMPLETED 2014-06-09 Kinki University Hospital, Osa... More >>ka, Japan Less <<
NCT00787033 Cancer PHASE1 COMPLETED 2025-02-12 Pfizer Investigational Site, B... More >>oston, Massachusetts, 02114, United States|Pfizer Investigational Site, Boston, Massachusetts, 02115, United States|Pfizer Investigational Site, Boston, Massachusetts, 02215, United States|Pfizer Investigational Site, Nashville, Tennessee, 37203, United States|Pfizer Investigational Site, Toronto, Ontario, M5G 2M9, Canada Less <<
NCT02004028 Malignant Pleural Mesothelioma PHASE2 TERMINATED 2019-06-19 Brigham and Women's Hospital, ... More >>Boston, Massachusetts, 02115, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.96mL

0.39mL

0.20mL

9.79mL

1.96mL

0.98mL

19.59mL

3.92mL

1.96mL

References

 

Historical Records

Categories